12 recruiting, 5 completed, 2 not yet recruiting, 2 withdrawn. 14 Phase 1, 8 Phase 2, 5 Early Phase 1.
Follow Juventas Cell Therapy Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies HY035 cell injection - Acute T Cell Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory | Phase 1 | Enrolling by invitation | Institute of Hematology & Blood Diseases Hospital, China | 13 | 2026-08-15 | 2026-08-25 |
| HY001N for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy. HY001N Cell Injection - Autoimmune Hemolytic Anemia (AIHA) | Phase 1 | Recruiting | Juventas Cell Therapy Ltd. | 9 | 2026-07-02 | 2026-08-05 |
| A Study of HY001N in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases HY001N cell injection - Neurological Autoimmune Diseases | Early Phase 1 | Not yet recruiting | Juventas Cell Therapy Ltd. | 15 | 2025-12-30 | 2025-12-04 |
| Inaticabtagene Autoleucel Injection in the Treatment of Autoimmune Hemolytic Anemia After Three or More Lines of Therapy Inaticabtagene Autoleucel Injection - AIHA - Cold Autoimmune Hemolytic Anemia | Phase 1 | Not yet recruiting | Juventas Cell Therapy Ltd. | 12 | 2025-12-27 | 2025-09-22 |
| Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma HY004 - Non-hodgkin Lymphoma | Phase 1 / Phase 2 | Withdrawn | Juventas Cell Therapy Ltd. | 2025-09-01 | 2025-08-08 | |
| A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL) HY004, Cyclophosphamide, Fludarabine Phosphate - B-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Withdrawn | Juventas Cell Therapy Ltd. | 2025-06-30 | 2025-08-08 | |
| A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases CNCT19 cell injection - Neurological Autoimmune Diseases | Early Phase 1 | Recruiting | Juventas Cell Therapy Ltd. | 18 | 2025-03-01 | 2026-03-05 |
| Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia Inaticabtagene autoleucel Injection - Autoimmune Thrombocytopenia | Phase 1 | Recruiting | Juventas Cell Therapy Ltd. | 12 | 2025-03-01 | 2025-08-07 |
| Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma anti-CD19 CAR-T - Advanced Hepatocellular Carcinoma | Phase 1 | Recruiting | Zhejiang University | 12 | 2025-01-10 | 2025-12-15 |
| Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission. Inaticabtagene autoleucel - B-cell Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2024-08-01 | 2024-11-05 |
| Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic Leukemia Autologous hematopoietic stem cell transplantation combined with CD19-CART - Acute Lymphoblastic Leukemia ALL | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2024-06-25 | 2024-09-23 |
| Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia B-cell Acute Lymphoblastic Leukemia | Recruiting | Juventas Cell Therapy Ltd. | 200 | 2024-06-05 | 2024-09-19 | |
| Long-term Observational Study of Patients Treated With Inaticabtagene Autoleucel Injection Inaticabtagene autoleucel Injection - B-cell Tumors | Recruiting | Juventas Cell Therapy Ltd. | 1000 | 2024-03-30 | 2025-08-07 | |
| CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy. CNCT19 CAR-T cell therapy - Autoimmune Hemolytic Anemia, Autologous CD19 CAR-T | Phase 1 | Active not recruiting | Institute of Hematology & Blood Diseases Hospital, China | 6 | 2024-02-04 | 2025-05-16 |
| A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric) single dose of CNCT19 - B-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Juventas Cell Therapy Ltd. | 47 | 2023-02-07 | 2025-08-12 |
| Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases single dose of CNCT19 - Lupus Erythematosus, Systemic | Early Phase 1 | Recruiting | Juventas Cell Therapy Ltd. | 24 | 2021-12-14 | 2025-02-10 |
| CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma CNCT19, Gemcitabine Injection, busulfan - Large B-cell Lymphoma | Phase 1 / Phase 2 | Completed | Institute of Hematology & Blood Diseases Hospital, China | 30 | 2021-01-01 | 2025-05-13 |
| Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia single dose of CNCT19 - Relapsed or Refractory Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Juventas Cell Therapy Ltd. | 100 | 2020-12-24 | 2025-08-08 |
| Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma single dose of CNCT19 - Non-Hodgkin's Lymphoma | Phase 2 | Recruiting | Juventas Cell Therapy Ltd. | 60 | 2020-10-26 | 2025-02-07 |
| A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia single dose of CNCT19 - Relapsed or Refractory Acute Lymphoblastic Leukemia | Phase 1 | Completed | Juventas Cell Therapy Ltd. | 10 | 2020-03-13 | 2023-03-28 |
Showing 20 of 26. Sign in to see all of them.
Recurrence (6) · Burkitt Lymphoma (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Anemia, Hemolytic, Autoimmune (3) · Hematologic Neoplasms (2) · Leukemia (2) · Lymphoma, Non-Hodgkin (2) · Leukemia, Myeloid, Acute (1) · Lupus Erythematosus, Systemic (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, T-Cell (1) · Neoplasm, Residual (1) · Neoplasms (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)
Busulfan (1) · Cyclophosphamide (1) · Gemcitabine (1) · Immunotherapy, Adoptive (1) · Melphalan (1) · fludarabine phosphate (1)
China (22)
Jianxiang Wang, Dr. (5) · Dehui Zou, Dr. (4) · Aibin Liang, Dr. (1) · Jianxiang Wang M.D. (1) · Jun Shi, Dr. (1) · Mengtao Li, Dr. (1) · Shengyun Liu (1) · Tingbo Liang, Professor (1) · Weili Zhao, Dr. (1) · Xiaofan Zhu, M.D (1) · Yi Zhang (1)
PMID 32894185, PMID 35622074, PMID 38631712, PMID 39626300, PMID 40960310, PMID 41429239, PMID 41534043